These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8895287)

  • 1. Importance of the organ-independent elimination of cisatracurium.
    Kisor DF; Schmith VD; Wargin WA; Lien CA; Ornstein E; Cook DR
    Anesth Analg; 1996 Nov; 83(5):1065-71. PubMed ID: 8895287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations.
    Chen C; Yamaguchi N; Varin F
    J Vet Pharmacol Ther; 2009 Dec; 32(6):571-6. PubMed ID: 20444012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of cisatracurium besilate.
    Kisor DF; Schmith VD
    Clin Pharmacokinet; 1999 Jan; 36(1):27-40. PubMed ID: 9989341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma.
    Welch RM; Brown A; Ravitch J; Dahl R
    Clin Pharmacol Ther; 1995 Aug; 58(2):132-42. PubMed ID: 7648763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia.
    Tran TV; Fiset P; Varin F
    Anesth Analg; 1998 Nov; 87(5):1158-63. PubMed ID: 9806701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination.
    Fisher DM; Canfell PC; Fahey MR; Rosen JI; Rupp SM; Sheiner LB; Miller RD
    Anesthesiology; 1986 Jul; 65(1):6-12. PubMed ID: 3755306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects.
    Wu Z; Wang S; Peng X; Lu C; Ye X; Wu B
    Drug Metab Dispos; 2016 Jan; 44(1):75-82. PubMed ID: 26470914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose proportionality of cisatracurium.
    Schmith VD; Fiedler-Kelly J; Phillips L; Grasela TH
    J Clin Pharmacol; 1997 Jul; 37(7):625-9. PubMed ID: 9243356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation.
    De Wolf AM; Freeman JA; Scott VL; Tullock W; Smith DA; Kisor DF; Kerls S; Cook DR
    Br J Anaesth; 1996 May; 76(5):624-8. PubMed ID: 8688259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
    Atherton DP; Hunter JM
    Clin Pharmacokinet; 1999 Mar; 36(3):169-89. PubMed ID: 10223167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients.
    Smith CE; van Miert MM; Parker CJ; Hunter JM
    Anaesthesia; 1997 Sep; 52(9):833-41. PubMed ID: 9349062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
    Panusitthikorn P; Suthisisang C; Tangsujaritvijit V; Nosoongnoen W; Dilokpattanamongkol P
    BMC Anesthesiol; 2022 Jan; 22(1):32. PubMed ID: 35065599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium?
    Weindlmayr-Goettel M; Gilly H; Kress HG
    Br J Anaesth; 2002 Apr; 88(4):555-62. PubMed ID: 12066733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation.
    Cammu G; Bossuyt G; De Baerdemaeker L; Den Blauwen N; Struys M; Mortier E
    J Clin Anesth; 2002 Mar; 14(2):135-9. PubMed ID: 11943528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction.
    Huang X; Chen L; Cai Y; Wei J; Lin L; Sun J; Peng X; Wang S
    BMC Anesthesiol; 2020 Jan; 20(1):21. PubMed ID: 31969113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose).
    Ward S; Neill EA; Weatherley BC; Corall IM
    Br J Anaesth; 1983 Feb; 55(2):113-8. PubMed ID: 6687550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia.
    Imbeault K; Withington DE; Varin F
    Anesth Analg; 2006 Mar; 102(3):738-43. PubMed ID: 16492821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome.
    Dhonneur G; Cerf C; Lagneau F; Mantz J; Gillotin C; Duvaldestin P
    Anesth Analg; 2001 Aug; 93(2):400-4 , 3rd contents page. PubMed ID: 11473869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro degradation of atracurium and cisatracurium at pH 7.4 and 37 degrees C depends on the composition of the incubating solutions.
    Weindlmayr-Goettel M; Kress HG; Hammerschmidt F; Nigrovic V
    Br J Anaesth; 1998 Sep; 81(3):409-14. PubMed ID: 9861132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.